Abstract
IgA nephropathy (IgAN) is most frequently found in chronic glomerulonephritis (CGN) in childhood, followed by Henoch-Schönlein purpura nephritis (HSPN), focal segmental glomerulosclerosis, and membranoproliferative glomerulonephritis. Recently, it has been reported that the pathogenesis of IgAN and HSPN may be associated with the circulation of defective forms of IgA1 or the presence of in situ immune complexes, and the onset and progression of inflammation are thought to be associated with complement components, activated macrophages and mesangial cells. To control these inflammations, the most beneficial treatment was chosen according to the severity of each disease. For children with severe CGN, the long-term prognosis was improved by multi-drug combination therapy including steroid and immunosuppressive drugs, plasmapheresis and LDL-apheresis. It is important to control CGN activity by minimum doses of steroids and immunosuppressive drugs. To establish the best treatment for the management of CGN, randomized control studies are required to provide evidence.
